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Abstract. Background: Colorectal cancer (CRC) is the
third most common type of cancer and the fourth most
frequent cause of cancer death. Literature indicates that
vascular endothelial growth factor is a predominant
angiogenic factor and that angiogenesis plays an important
role in the progression of CRC. Patients and Methods: The
present series consisted of tissue samples obtained from 672
patients who had undergone large bowel resection between
2005 and 2010 at the Braga Hospital, Portugal. Archival
paraffin-embedded CRC tissue and normal adjacent samples
were used to build up tissue microarray blocks and VEGF-A,
VEGF-C, VEGFR-2 and VEGFR-3 expression was
immunohistochemically assessed. Results: We observed an
overexpression of VEGF-C in CRC when tumour cells and
normal-adjacent tissue were compared (p=0.004). In tumour
samples, VEGF-C-positive cases were associated with
VEGFR-3 expression (p=0.047). When assessing the
correlation between VEGF-A, VEGF-C, VEGFR-2 and
VEGFR-3 expressions and the clinicopathological data, it
was revealed that VEGF-A positive cases were associated
with male gender (p=0.016) and well-differentiated tumours
(p=0.001); VEGF-C with colon cancers (p=0.037), exophytic
(p=0.048), moderately-differentiated  (p=0.007) and T3/T4
(p=0.010) tumours; VEGFR-2 with invasive adenocarcinoma
(p=0.007) and VEGFR-3 with the presence of hepatic
metastasis (p=0.032). Overall survival curves for CRC were
statistically significant for rectal cancer, VEGF-C expression
and stage III (p=0.019) and VEGFR-3 expression and stage
IV (p=0.047). Conclusion: Quantification of VEGF-A,
VEGF-C, VEGFR-2 and VEGFR-3 expression seems to
provide valuable prognostic information in CRC and the
correlation with clinicopathological data revealed an
association with characteristics that contribute to
progression, invasion and metastasis leading to poorer
survival rates and prognosis.
Colorectal cancer (CRC) is the third most common type of
cancer (1-4) and the fourth most frequent cause of cancer
death (1-5). Globally, CRC incidence varies widely, with
higher rates in North America, Australia and western Europe,
and the lowest rates in developing countries (4, 6), although
in recent years, increasing CRC rates have been reported in
these countries (4, 7). According to the World Health
Organization (WHO), CRC is one of the most prevalent
diseases of the occident world (4, 8) and the second most
common cause of death from malignant diseases in Western
countries (4, 9, 10). Despite improvements in treatment,
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mortality remains high, with metastatic spread to the liver
occurring in approximately 50% of patients (10) . In
Portugal, data from Statistics Portugal revealed that CRC is
the second most common type of cancer, after gastric cancer,
with an incidence of 5,000 individuals year and one of the
main causes of death from neoplastic disease (11). 
Angiogenesis plays a key role in tumorigenesis and
metastatic processes (1, 12, 13). It consists of the formation
of new blood vessels from the endothelium of pre-existing
vasculature (2, 13). Tumour angiogenesis is essential for
neoplastic mass development, favouring access to the blood
components and also strengthening the vascular routes in the
metastatic process (14-16). Neovascularisation as a whole,
promotes tumour growth by supplying nutrients, oxygen and
releasing growth factors that promote tumour cell
proliferation (13, 14, 17-19). 
Numerous studies have demonstrated that tumour
overexpression of vascular endothelial growth factor (VEGF)
is associated with advanced tumour stage or tumour
invasiveness in various types of common human cancer (13,
20-22), and its overexpression in colonic cancer tissue indicates
poor prognosis (22); although paradoxically, some data showed
that VEGF has no  significant prognostic value in colon cancer
tissue (23). VEGF-A is the most widely studied angiogenic
factor; it increases vascular permeability and is the main
angiogenic protein known (4, 12, 19-20, 23-25). 
In this study, we evaluated the expression of VEGF-A,
VEGF-C, and their receptors VEGFR-2 and VEGFR-3 in a
series of 672 cases and determined their correlation with
clinicopathological parameters.
Materials and Methods
Data from 672 patients treated in the Braga Hospital, North of
Portugal, between January 1st 2005 and January 1st 2010 with CRC
diagnosis and submitted to surgical treatment was collected
prospectively. The data collected from clinical and preoperative
diagnostic examinations included: age, gender, clinical presentation,
oncologic history, tumour localization, histological type,
macroscopic appearance and preoperative staging. The tumour
localization was recorded and classified as colon and rectum
(between anal verge and 15 cm at rigid rectoscopy). Operative
reports made by surgeons included data such as the presence of
perforation; information about tumour mobility and type of surgery
was also collected. Histopathological reports included: tumour
extent (T), extent of spread to the lymph nodes (N), presence of
distant metastasis (M), tumour differentiation, resection margins
involvement and lymphatic and blood vessel invasion. The level of
positive lymph nodes was not described in all specimens. The
histological type of CRC was determined by two experienced
pathologists and tumour staging was graded according to the TNM
Classification of Malignant Tumours (TNM), sixth edition (25).
A series of formalin-fixed, paraffin-embedded tissues from
these patients was analyzed by immunohistochemistry for VEGF-
A, VEGF-C, VEGFR-2 and VEGFR-3 expression. Slides from all
672 specimens were reviewed and mapped and tissue microarrays
were built using a manual tissue arrayer (MTA-1 Beecher
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Table I. Detailed aspects of the immunohistochemical procedure used to visualize the different proteins.
Protein marker Antigen retrieval Peroxidase inactivation Detection system Antibody
Company Dilution Incubation 
period
VEGF-A EDTA buffer 1× 3% H2O2 in methanol, LabVision Abcam Cambridge, 1:100 Overnight, 4˚C
pH=8.0 10 min. Cambridgeshire, UK
VEGF-C EDTA buffer 1× 3% H2O2 in methanol, LabVision Invitrogen Carlsbad, 1:200 Overnight, 4˚C
pH=8.0 10 min. California, US
VEGF-R2 Citrate buffer 0.01 M 3% H2O2 in methanol, LabVision Abcam Cambridge, 1:200 Overnight, 4˚C
pH=6.0 10 min. Cambridgeshire, UK
VEGF-R3 Citrate buffer 0.01 M 3% H2O2 in methanol, LabVision Abcam Cambridge, 1:100 Overnight, 4˚C
pH=6.0 10 min. Cambridgeshire, UK
Table II. Pattern of protein staining in tumour versus normal adjacent
epithelium (NAE). *Examined for statistical significance using the
Fisher’s exact test (when n<5). 
Protein marker Immunoreaction
n Positive (%) p-Value
VEGF-A
NAE 132 130 (98.5%) 1.000*
Tumour 500 490 (98.0%) 
VEGF-C
NAE 138 115 (83.3%) 0.004
Tumour 508 466 (91.7%) 
VEGFR-2
NAE 142 133 (93.7%) 0.064
Tumour 501 486 (97.0%) 
VEGFR-3
NAE 139 34 (24.5%) 0.903
Tumour 505 121 (24.0%) 
Instrument, Silver Spring, MD, USA). Representative areas of the
CRC lesions were selected and cores of 1.0 mm in diameter were
twice-sampled and arranged at 0.3 mm from each other in the
recipient paraffin block. A database was built for every block
produced, including the coordinates of each core and case of
origin. Comparison of expression in tumour versus normal cells
was also possible since, in most cases, the same paraffin section
contained both neplastic and normal colonic epithelium. VEGF
immunohistochemical expression was correlated with the
available clinicopathological data. All cases in this study were
identified using a series of unified codes, for the following
review. The study protocol was approved by the Ethics Committee
of the Braga Hospital.
Immunohistochemistry. Tissue microarray (TMA) protein expression
was evaluated by immunohistochemistry. Briefly, after de-
paraffinization and rehydration, 3 μm sections were immersed in
0.01 M citrate buffer (pH 6.0) and heated at 98˚C for 20 min for
epitope antigen retrieval. Subsequently, endogenous peroxidase was
blocked with 0.3% hydrogen peroxide in methanol. The primary
antibody incubation step take place overnight at 4˚C.  Visualization
was developed with 3,3’-diaminobenzidine (DAKO Corporation,
Carpinteria, CA, USA) and counterstaining with Harris’s
haematoxylin (Merck, Dermstadt, Germany). Negative controls were
obtained by omitting the primary antibody incubation step and
tonsils were used as positive control. 
Details of the procedure used for each antibody are found in
Table I. After the immunohistochemical procedure, the slides were
evaluated and then photographed under a microscope. 
Immunohistochemical evaluation. Sections were scored semi-
quantitatively for the extent of immunoreaction as follows: 0: 0%
of immunoreactive cells; 1: <5% of immunoreactive cells; 2: 5;
50% of immunoreactive cells; and 3: >50% of immunoreactive
cells. The intensity of staining was scored semi-qualitatively as 0:
negative; 1: weak; 2: intermediate; and 3: strong. The final score
for the immunoreaction was defined as the sum of both parameters
(extent and intensity), and grouped as negative, 0, weak, 2,
moderate, 3, and strong, 4;6. For statistical purposes, only the
moderate and strong immunoreaction final scores were considered
as positive. Evaluation of VEGF immunohistochemical expression
was performed blindly by two independent observers and
discordant cases were discussed under a double-head microscope
in order to determine a final score.
Statistical analysis. All data were collected and stored in an Excel
PC database and statistically analyzed using the Statistical Package
for the Social Sciences, version 19.0 (SPSS Inc., Chicago, IL,
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Table III. Assessment of associations between expression of VEGF-A and VEGF-C and the receptors VEGFR-2 and VEGFR-3 in tumour cases. 
VEGFR-2 VEGFR-3
n Positive n (%) p-Value n Positive n (%) p-Value
VEGF-A-positive 464 453 (97.6%) 1.000 471 120 (25.5%) 0.210
VEGF-C-positive 446 434 (97.3%) 1.000 451 117 (25.9%) 0.047
Table IV. Assessment of correlation between VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression and clinical data. *Examined for statistical
significance using Fisher’s exact test (when n<5).
Protein marker VEGF-A VEGF-C VEGFR-2 VEGFR-3
n Positive (%) p-Value n Positive (%) p-Value n Positive (%) p-Value n Positive (%) p-Value
Gender
Male 304 99.3 0.016* 309 91.6 0.446 306 97.1 0.776* 307 24.4 0.731
Female 181 96.1 184 93.5 179 97.8 182 25.8
Age, years       
≤71.5 242 97.9 1.000* 249 90.4 0.107 244 97.1 0.802 247 23.9 0.565
>71.5 242 98.3 229 94.2 240 97.5 241 26.1
Personal history-polyps
Negative  419 98.3 0.352* 427 92.0 0.804* 420 97.4 0.689* 423 25.8 0.289
Positive 66 97.0 66 93.9 65 96.9 66 19.7
CRC
Negative 472 98.3 0.219* 480 92.3 1.000* 472 97.2 1.000* 476 25.2 0.533*
Positive 13 92.3 13 92.3 13 100.0 13 15.4
Cancer
Negative 446 98.2 0.533* 454 91.6 0.060 447 97.1 0.612* 450 25.6 0.292
Positive 39 97.4 39 100.0 38 100.0 39 17.9
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Figure 1. Immunohistochemical expression of VEGF-A, VEGF-C, VEGF-R2 and VEGF-R3 in colorectal cancer samples (original magnification ×40). 
USA). All comparisons were examined for statistical significance
using Pearson’s chi-square (χ2) test and the Fisher’s exact test (when
n<5), with the threshold for significant p-values of less than 0.05.
Survival curves were determined for overall survival by the
Kaplan–Meier method.
Results
VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expressions in
CRC samples. A total of 672 samples were organized into
TMAs, including tumour and normal adjacent epithelium
(NAE). Sections were evaluated for immunoexpression and
the obtained results are given in Table II, which summarizes
the frequency of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-
3 expression in tumour cells and NAE.
When analyzing the results of Table II, it can be seen that
only VEGF-C is overexpressed in tumours when tumour
cells and NAE are compared (p=0.004), and VEGFR-2
shows a tendency to be differently expressed (p=0.064). 
Figure 1 shows representative cases of positive staining
for VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 in tumour
cells and in NAE.
Associations between VEGF-A, VEGF-C and VEGFR-2,
VEGFR-3 expression in CRC tissues. We analyzed the
associations between the expression of VEGF-A, VEGF-C and
the receptors VEGFR-2 and VEGFR-3 in CRC tissues and
observed that in the tumour samples, VEGF-C positivity was
associated with VEGFR-3 positivity (p=0.047) (Table III).
Associations between VEGF-A, VEGF-C, VEGFR-2 and
VEGFR-3 expressions in CRC tissues and clinical data. An
assessment of the correlation between the expression of
VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 and the clinical
data revealed that VEGF-A-positive cases were less frequently
associated with female gender (p=0.016) and VEGF-C had a
tendency to  be associated with a personal history of CRC
(p=0.060) Table IV.
When analyzing the correlation with data from
diagnosis/surgery, we found an association between VEGF-C
expression and tumour localized in colon (p=0.037) and a
exophytic macroscopic cancer appearance (p=0.048).
VEGFR-3 shows an association with the presence of hepatic
metastasis’ (p=0.032) Table V. 
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Table V. Assessment of correlation between VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression and  diagnostic/surgical data. *Examined for
statistical significance using Fisher’s exact test (when n<5).
Protein marker VEGF-A VEGF-C VEGFR-2 VEGFR-3
n Positive (%) p-Value n Positive (%) p-Value n Positive (%) p-Value n Positive (%) p-Value
Presentation
Asymptomatic 87 96.6 0.207* 89 88.8 0.168 87 97.7 1.000* 88 23.9 0.795
Symptomatic    398 98.5 404 93.1 398 97.2 401 25.2
Rectal examination 
Mobile tumour 40 97.5 1.000* 42 81.0 0.300* 40 90.0 1.000* 40 25.0 0.339*
Fixed tumour 25 100.0 25 92.0 25 92.0 24 12.5
Localization
Colon 352 98.3 0.711* 357 93.8 0.037 354 98.0 0.115 358 24.6 0.756
Rectum 133 97.7 136 88.2 131 95.4 131 26.0
Macroscopic appearance
Polypoid 244 98.0 0.896 255 89.8 0.048 246 98.0 0.278 252 25.4 0.439
Ulcerative 112 97.4 115 94.8 115 98.3 114 25.4
Infiltrative 38 97.4 39 94.9 40 97.5 38 13.2
Exophytic 38 100.0 37 97.4 35 92.1 39 28.2
Villous 2 100.0 1 50.0 2 100.0 2 50.0
CEA (ng/ml)
>5 314 94.9 1.000* 314 90.1 0.869 314 93.9 0.756 313 24.6 0.779
≥5 78 93.6 78 89.7 78 94.9 78 23.1
Hepatic metastasis
Absent 443 98.2 0.535* 450 92.2 1.000* 443 97.1 0.613* 445 23.8 0.032
Present 39 97.4 40 92.5 39 100 41 39.0
Tumour mobility 
Mobile 418 97.8 0.240 426 91.8 0.158 419 97.4 0.786 423 24.6 0.630
Fixed 63 100.0 63 96.8 62 96.8 62 27.4
Tumour perforation
Absent 460 98.0 0.480 468 92.3 1.000* 461 97.6 0.079 464 24.6 0.403
Present 25 100.0 25 92.0 24 91.7 25 32.0
When analysing the correlation with pathological data, we
found an association between the expression of VEGF-A and
well-differentiated tumours (p=0.001); VEGF-C and
moderately-differentiated (p=0.007) and T3/T4 penetration
tumours (p=0.010); VEGFR-2 expression and invasive
adenocarcinoma (p=0.007) Table VI.
Overall survival curves according to expression of VEGF-A,
VEGF-C, VEGFR-2 and VEGFR-3. A statistically significant
association between VEGF-C expression and stage III rectal
cancer (p=0.019) and VEGFR-3 expression and stage IV
rectal cancer (p=0.047) was found Figures 2-7.
Discussion
Our results corroborate the premise that angiogenesis plays a
key role in tumourigenesis and metastatic processes (1, 12,
13), because all the markers involved in neovascularization
were consistently expressed in tumour cells. Additionally,
VEGF-C, a lymphangiogenic marker was significantly over-
expressed in cancer cells rather than in normal counterparts.
This general view of our results clearly indicates that CRCs
are predominantly composed of cancer cells that are directly
or indirectly associated with the high expression of
molecules related to blood neovascularization (angiogenesis)
and that the major lymphangiogenic molecules are also
importantly expressed in cancer cells.
Normally, the VEGF family is weakly-expressed in a wide
variety of human and animal tissues; however, high levels of
VEGF expression can be detected at sites where physiological
angiogenesis is required, such as foetal tissue or placenta and
in a vast majority of human tumours and some other diseases
e.g. chronic inflammatory disorders, diabetes mellitus, and
ischemic heart disease (4). Furthermore, both the VEGF
family and its receptors are expressed at high levels in
metastatic human colon carcinomas and in tumour-associated
endothelial cells, respectively (4, 20). Consequently, VEGF is
recognized as a prominent angiogenic factor in colon
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Table VI. Assessment of correlation between expression of VEGF-A, VEGF-C, VEGF-R2 and VEGF-R3 pathological data. *Examined for statistical
significance using Fisher’s exact test (when n<5).
Protein marker VEGF-A VEGF-C VEGFR-2 VEGFR-3
n Positive (%) p-Value n Positive (%) p-Value n Positive (%) p-Value n Positive (%) p-Value
Tumor size
≤4.5 cm 281 97.5 0.161* 281 94.3 0.088 276 98.2 0.291 277 27.1 0.287
>4.5 cm 175 99.4 181 90.1 178 96.6 181 22.7
Histological type
Adenocarcinoma 403 98.3 0.869 408 92.6 0.470 404 98.0 0.007 403 26.1 0.214
Mucinous 50 98.0 52 90.4 49 93.9 53 15.1
Invasive 25 96.0 25 96.0 24 100.0 25 28.0
Signet ring & mucinous 3 100.0 4 75.0 4 75.0 4 0.0
Differentiation
Well 209 99.0 0.001 215 92.6 0.007 210 97.1 0.973 212 23.6 0.474
Moderate 208 97.6 208 94.2 205 97.6 206 27.7
Poor 48 97.9 48 89.6 47 97.9 49 22.4
Undifferentiated 2 66.7 4 50.0 4 100.0 4 0.0
Tumour penetration
Tis 5 100.0 0.476 5 80.0 0.010 4 100.0 0.939 5 20.0 0.830
T1/T2    87 96.6 88 85.2 87 97.7 85 27.1
T3/T4     387 98.4 394 94.2 388 97.4 393 24.2
Spread to lymph nodes
Absent 277 97.8 0.742* 276 92.4 0.767 273 97.4 0.782* 273 24.2 0.696
Present 194 98.5 203 93.1 198 97.0 202 25.7
Vessel  invasion
Absent 166 98.2 0.889 166 92.2 0.988 163 97.5 0.747 164 23.2 0.578
Present 301 98.0 308 92.2 303 97.0 306 25.5
TNM stage
0 1 100.0 0.713 1 100.0 0.336 1 100.0 0.940 1 0.0 0.550
I 76 96.1 76 86.8 75 98.7 74 28.4
II 183 98.4 181 94.5 180 97.2 180 21.7
III 147 98.6 156 92.3 150 96.7 154 24.7
IV 70 98.6 71 93.0 70 97.1 72 30.6
carcinoma and the assessment of VEGF expression may be
useful in predicting metastasis from CRC (4, 20). In fact,
VEGF-A expression was found to be higher in patients with
metastatic tumours than in those with non-metastatic tumours
(4, 20, 26), and high levels of VEGF-A expression were
associated with advanced cancer stage and related to an
unfavourable prognosis (4, 22, 23, 27). Other studies have
shown that VEGF-A is also a useful marker for prognosis by
significantly correlating with angio-lymphatic invasion, lymph
node status and depth of invasion, although it was not an
independent prognostic factor (4, 14, 24).
The effect of VEGF depends not only on tumour cell
expression of VEGF, but also on that of VEGF-R in the
endothelial cells (4, 13). The ligands of the VEGF family
include VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-
E; and the receptors are VEGFR-1, -2 and -3 (4, 28). 
In literature, the role of the VEGF family members in
CRC has, to date, mainly concentrated on VEGF-A, but the
newer members of the family, VEGF-C and VEGF-D, may
have important roles to play in both angiogenesis and
lymphangiogenesis (29).
VEGF-A promotes angiogenesis through enhancement of
permeability, activation, survival, migration, invasion, and
proliferation of endothelial cells (4, 30). VEGF-A plays a
role in early tumour development at the stage of adenoma
formation (4, 10, 31) and some studies documented an
overexpression of VEGF-A in CRC (4, 24).
The VEGF-C gene was also found to be poorly expressed,
with only moderate overexpression in CRCs compared to
control tissues (29, 32); however, the number of samples studied
was very small (n=12). In a larger series of patients, the
immunohistochemical expression of VEGF-C was correlated
with lymph node spread (29, 33). In our study, contrary to what
is found in literature, we did not observe a statistically positive
relation between VEGF-A expression in tumours and NAE. We
observed that VEGF-C is overexpressed in tumours when
comparing tumour cells with NAE (p=0.004), and VEGFR-2
shows a tendency for a similar association (p=0.064).
We also analyzed the associations between expression of
VEGF-A, VEGF-C and the receptors  VEGFR-2 and
VEGFR-3 in CRC tissues and observed that in tumour
samples,  VEGF-C positivity was associated with VEGFR-3
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Figure 2. Survival curve of patients with stage III rectal cancer
according to VEGF-C expression, assessed by the log-rank test
(p=0.019).
Figure 3. Survival curve of patients with stage IV rectal cancer
according to VEGFR-3 expression, assessed by the log-rank test
(p=0.047).
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expression (p=0.047); this is consistent with the results
mentioned above, where lymphangiogenesis induced by
VEGF-C is driven mainly by the activation of the tyrosine
kinase-linked receptor VEGFR-3 (34). This receptor occurs
in embryonic vascular endothelial cells, where its production
decreases during development and is subsequently restricted
to lymphatic vessels after vascular net formation (35). Many
experimental studies have indicated that VEGFR-3 and its
ligands (VEGF-C and -D) stimulate lymphangiogenesis in
tumours and induce proliferation and growth of new
lymphatic capillaries, enhancing the incidence of lymph node
metastasis (36-40).
The comparison of VEGF-A, VEGF-C, VEGFR-2 and
VEGFR-3 expressions and the clinicopathological data, data
from diagnosis/surgery and pathological data revealed that
VEGF-A-positive cases were associated with male gender
(p=0.016) and well-differentiated tumours  (p=0.001);
VEGF-C expression with cancers localized in colon
(p=0.037), exophytic (p=0.048), moderately-differentiated
(p=0.007) and T3/T4 penetrating tumours (p=0.010);
VEGFR-2 shows an association with invasive
adenocarcinoma (p=0.007) and VEGFR-3 with the presence
of hepatic metastasis (p=0.032). All of these characteristics
contribute to progression, invasion and metastasis, and poorer
survival and prognosis, as stated in literature to be associated
with VEGF-A overexpression in CRC (4, 30). Moreover
VEGF-C overexpression in CRC has been found to correlate
with lymphatic invasion and lymph node metastasis (41).
Increased VEGF-C mRNA expression in tumour tissues was
also documented to be positively correlated with lymphatic
metastasis and poor prognosis (42). In our series, we reported
significantly poor survival when we correlated overall
survival with VEGF-C in stage III rectal cancer (p=0.019)
and VEGFR-3 expression in stage IV (p=0.047).
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